文献速递其他结缔组织病

Sarilumab治疗多关节型幼年特发性关节炎:2b期开放标签多中心研究剂量探索与1年分析

Sarilumab in Polyarticular-Course Juvenile Idiopathic Arthritis: Dose-Finding and 1-Year Analysis of a Phase 2b, Open-Label, Multicenter Study.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2026-03-24

该2b期开放标签多中心研究评估Sarilumab治疗多关节型幼年特发性关节炎(pcJIA),在两部分体重组中评估三种剂量以选择最优剂量,主要终点为药代动力学暴露。从基线开始接受选定剂量(A/B组:3.0/4.0 mg/kg 每2周)的73例患者中,第48周JIA-ACR 30%、50%、70%、90%改善率分别为100%、100%、93.8%、76.6%,安全性特征与Sarilumab已知特征一致。

要点

  • 选定剂量为A/B组:3.0/4.0 mg/kg 每2周,稳态Cmax、AUC0-14天、Ctrough在A/B组分别为27.1/40.4 mg/L、276/395-day*mg/L、9.57/14.4 mg/L。
  • 从基线接受选定剂量的73例患者第48周JIA-ACR 30%、50%、70%、90%改善率分别为100%、100%、93.8%、76.6%。
  • 73例中70例(95.9%)报告不良事件,27例(37%)发生3/4级中性粒细胞减少,无相关感染,无死亡。

核心结论

  • 在从基线接受选定剂量的pcJIA患者中,药代动力学暴露与成人类风湿关节炎200 mg每2周剂量相当,疾病活动度观察到临床相关改善,安全性特征与Sarilumab已知特征一致。

研究设计与样本

  • 2b期开放标签多中心研究(NCT02776735),由三个序贯部分(每部分含核心治疗期和扩展期)组成,共治疗101例患者(76.2%女性,平均年龄9.4岁)。
  • 第1部分在两个体重组(A/B组:≥30-60 kg/≥10至<30 kg)中评估三种剂量以选择最优剂量,第1部分扩展期中初始未分配至选定剂量的患者转换为选定剂量,第2、3部分患者从基线接受选定剂量。
  • 主要终点为药代动力学暴露(AUC0-τ、Cmax、Ctrough),同时评估安全性和疗效。

主要发现

  • 第1部分评估的剂量中选定剂量2(A/B组:3.0/4.0 mg/kg 每2周)。
  • 从基线接受选定剂量患者(n=73)稳态时A/B组Cmax分别为27.1/40.4 mg/L,AUC0-14天分别为276/395-day*mg/L,Ctrough分别为9.57/14.4 mg/L。
  • 第48周JIA-ACR 30%、50%、70%、90%改善率分别为100%、100%、93.8%、76.6%。
  • 73例中70例(95.9%)报告不良事件,27例(37%)发生3/4级中性粒细胞减少,无相关感染,无死亡。

关键数值与推荐

  • 选定剂量:A/B组分别为3.0/4.0 mg/kg 每2周。
  • 从基线接受选定剂量患者(n=73)稳态时A/B组Cmax为27.1/40.4 mg/L,AUC0-14天为276/395-day*mg/L,Ctrough为9.57/14.4 mg/L。
  • 第48周JIA-ACR 30%、50%、70%、90%改善率分别为100%、100%、93.8%、76.6%。
  • 不良事件70/73例(95.9%),3/4级中性粒细胞减少27例(37%),无相关感染,无死亡。

临床怎么用

  • 在pcJIA患者中,A/B组分别使用3.0/4.0 mg/kg 每2周剂量时,药代动力学暴露与成人类风湿关节炎200 mg每2周剂量相当。
  • 该剂量下第48周观察到JIA-ACR 30%、50%、70%、90%改善率分别为100%、100%、93.8%、76.6%。
  • 安全性方面,95.9%患者报告不良事件,37%发生3/4级中性粒细胞减少,无相关感染,无死亡。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study assessed sarilumab in treating patients with polyarticular-course juvenile idiopathic arthritis (pcJIA). METHODS: This phase 2b, open-label study (NCT02776735) consisted of three sequential parts (each with a core-treatment and extension phase). During part 1, three doses were assessed in two weight groups (group A/B: ≥30-60 kg/≥10 to <30 kg) to select the optimal dose with regard to pharmacokinetics, safety and efficacy were evaluated in latter parts. During the extension phase of part 1, patients initially assigned to the selected optimal dose continued on this dose; the remaining patients were switched to this selected dose. Patients in parts 2 and 3 received the selected dose from baseline. The primary endpoint was pharmacokinetic exposure (area under the serum concentration versus time curve during a dose interval Շ of 2 weeks [AUC0-Շ], maximum serum concentration observed [Cmax], and concentrations observed before treatment administration during repeated dosing [Ctrough]). Safety and efficacy were assessed. RESULTS: The mean age of treated patients (N = 101; 76.2% female) was 9.4 years. Of the evaluated doses in part 1, dose 2 (group A/B: 3.0/4.0 mg/kg every 2 weeks [q2w]) was selected. In patients receiving the selected dose from baseline (n = 73), Cmax, AUC0-14 days and Ctrough at steady state in group A/B were 27.1/40.4 mg/L, 276/395-day*mg/L, and 9.57/14.4 mg/L, respectively. At week 48, the JIA-American College of Rheumatology 30%, 50%, 70%, and 90% improvement criteria rates were 100%, 100%, 93.8%, and 76.6%, respectively. Adverse events were reported in 70 of 73 patients (95.9%). Twenty-seven patients (37%) experienced grade 3/4 neutropenia; there were no associated infections. No deaths occurred. CONCLUSION: In patients with pcJIA receiving the selected dose from baseline, pharmacokinetic exposure was comparable to a dose of 200 mg q2w for adults with rheumatoid arthritis. Clinically relevant improvements were observed in disease activity, with safety being consistent with the known profile of sarilumab.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. De Benedetti F, Penadés IC, Nikishina I, et al. Sarilumab in Polyarticular-Course Juvenile Idiopathic Arthritis: Dose-Finding and 1-Year Analysis of a Phase 2b, Open-Label, Multicenter Study. Arthritis Care Res (Hoboken). 2026. PMID: 41235938. doi:10.1002/acr.25692

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。